Last updated 2026-08-21
- Raised $10M Series C led by GreyBird Ventures, Dec 2024
- Raised $10M Series B led by GreyBird Ventures, May 2024
- Raised $18.9M grant led by European Union's EIC Fund, Mar 2022
Total raised
$54.9M
Last: Grant 2026-05
Stage
Series A
Founded
2018
Headcount
41
HQ
Tel Aviv-Yafo, Israel
Sector
Biotechnology
About
NeuroKaire (formerly Genetika+) is a biotechnology company specializing in precision medicine in psychiatry and neurology. They have developed a personalized medical testing tool that uses a "brain-in-a-dish" technology to analyze patient-derived neurons, genetics, and medical history to identify optimal antidepressant treatments. This approach aims to eliminate the trial-and-error process in treating depression, leading to faster treatment, fewer side effects, and lower dosing. NeuroKaire's technology also provides pharmaceutical companies with tools for targeted drug discovery and development. NeuroKaire's R&D center, employing 25 people, is based in Tel Aviv, while they expanded to the US in 2023 and opened a commercial lab in Kearny, NJ.
Funding history · 9 rounds · $54.9M total
9 events/rounds · $54.9M Total Funding: $32.0M in Private Equity
Jun 2026
Dec 2024
May 2024
B Round
$10.0M
pitchbook.com
Mar 2022
Grant
$18.9M
calcalistech.com
★ European Union's EIC Fund★ European Innovation Council★ Israel Innovation Authority★ European Union's Horizon program★ European Union's EIC Accelerator program★ European Innovation Council (EIC) Accelerator★ European Commission's European Innovation CouncilEuropean CommissionEuropean Innovation Council (EIC) Accelerator program
Sep 2021
★ Meron Capital★ GreyBird VenturesCalcalistHoward MorganMichael ZeisserJumpspeed VenturesSapir Venture PartnersHilltop Venture PartnersEuropean Innovation CouncilMichael Zeisser of FMZ VenturesHoward Morgan Chairman of B Capital Group
Dec 2020
Grant
Undisclosed
pitchbook.com
Jul 2020
Grant
$3.0M
calcalistech.com
Oct 2019
Nov 2018
Pre-Seed
Undisclosed
pitchbook.com
★ MassChallenge
Headcount over time
41 employees (2026-09) · 1 point
Offices
Tel Aviv-Yafo, Israel · HQ / main office
Show all offices (1 more)
- Kearny, United States
Q&A
- What is NeuroKaire's primary focus?
- NeuroKaire is a biotechnology company specializing in precision medicine in psychiatry and neurology, aiming to transform depression medication selection by understanding individual patient responses.
- When was NeuroKaire founded?
- NeuroKaire was founded in 2018.
- How many employees does NeuroKaire currently have?
- NeuroKaire has 36 employees, falling within the 11-50 employee bucket.
- What was NeuroKaire's most recent funding round?
- NeuroKaire secured a Grant round in May 2026, raising $1,000,000.
- Which investors participated in NeuroKaire's A Round in December 2024?
- GreyBird Ventures led NeuroKaire's A Round in December 2024.
- What significant funding did NeuroKaire receive in July 2022?
- In July 2022, NeuroKaire received a Grant of $17,300,000 from the European Commission's European Innovation Council.
- Where are NeuroKaire's main operations located?
- NeuroKaire's R&D center is in Tel Aviv, Israel, and they expanded to the US in 2023 with a commercial lab in Kearny, NJ.
- What is the core technology behind NeuroKaire's personalized medical testing tool?
- NeuroKaire's personalized medical testing tool utilizes "brain-in-a-dish" technology to analyze patient-derived neurons, genetics, and medical history.
Team · 18
Talia Cohen Solal
Founder · CEO & Co-Founder
Daphna Laifenfeld
Founder · CSO & Co-Founder
Issar Yazbin
Chief Product Officer
David Pattison
VP of Business Development
Gosia Jaremko
Chief Laboratory Officer
Orit Goldman
VP of Stem Cell Product
Etay Aloni
VP of Imaging
Justin Coffey
CMO
Scott Gazelle
Chairman
Tom Miller
Board Member
Joshua A. Gordon
Chair of Psychiatry (Scientific Advisory Board)
Maurizio Fava
Psychiatrist-in-Chief (Scientific Advisory Board)
Stephen M. Stahl
Adjunct Professor (Scientific Advisory Board)
Michael Thase
Professor of Psychiatry (Scientific Advisory Board)
Mark Weiser
Chairman of Psychiatry (Scientific Advisory Board)
Barbara Corneo
Associate Professor (Scientific Advisory Board)
Jessica Tenebaum
Assistant Professor (Scientific Advisory Board)
Alexander Harris
executives
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2BB2C
Highlights
1 PatentsVerified
Tags
clinical-trialsneurologygenetic-engineeringpharma-companiesdeep-learningmental-healthmachine-learningdigital-healthcaremedicationdoctorspersonalizationtestingartificial-intelligenceclinicshealthcare-providerspatientsneurosciencehospitalspsychiatrydecision-support
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neurokaire.com |
|---|---|
| linkedin.com/company/28148811 | |
| facebook.com/genetikaplus | |
| YouTube | youtube.com/channel/UCPrzpeKog5qfli5T6faeSTw |
Identifiers & details
| Legal name | GenetikaPlus Ltd |
|---|---|
| Former names | Genetika+, GENETIKA RX |
| Founded | 2018 |
| Employees (exact) | 41 |
| Offices | Kearny |
Radar intelligence
Web history (Wayback)
| Domain | neurokaire.com |
|---|
Certificate / subdomain footprint
| Subdomains | 10 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515897205 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2018-08-30 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | אלון יגאל 126 תל אביב - יפו |